A recent report published in the journal Communications Medicine has shed light on the potential benefits of Paxlovid in treating long Covid. The study, which focused on 13 patients with the condition, found that while some individuals experienced improvements after taking the antiviral drug, the effects were not consistent across all participants.
Kate Leslie, a long Covid patient from Boulder, Colo., shared her experience with the debilitating symptoms she faced after contracting the virus in March 2022. Despite being healthy and athletic prior to her infection, Leslie described feeling as if she had a concussion, struggling with cognitive functions and communication.
The report highlighted that out of the 13 patients studied, nine reported some level of improvement after taking Paxlovid, but only five noted that the benefits were sustained. Additionally, four patients reported no improvement at all, underscoring the variability in response to the treatment.
The uncertainty surrounding which patients may benefit from Paxlovid and the duration of its effects signifies the ongoing challenges in finding effective treatments for long Covid. Alison Cohen, an epidemiologist at the University of California, San Francisco who co-authored the report and is also a long Covid patient, emphasized the urgent need for solutions to help those suffering from the lingering effects of the virus.
Despite the promising potential of Paxlovid in preventing severe illness during active Covid infections and potentially addressing remnants of the virus in the body, more research is needed to determine its efficacy in treating long Covid on a broader scale. As the medical community continues to explore various therapies and medications, the quest for effective treatments for long Covid remains a slow and complex process.